An Interdisciplinary Diagnostic Approach to Guide Therapy in C3 Glomerulopathy

GND
1077754574
Zugehörigkeit
III. Department of Medicine, University Medical Center Hamburg-Eppendorf ,Hamburg ,Germany
Schmidt, Tilman;
Zugehörigkeit
Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Hans-Knöll-Institute ,Jena ,Germany
Afonso, Sara;
Zugehörigkeit
Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Hans-Knöll-Institute ,Jena ,Germany
Perie, Luce;
Zugehörigkeit
Medical Alliance, eleva GmbH ,Freiburg ,Germany
Heidenreich, Karin;
Zugehörigkeit
Nephropathology Section, Institute of Pathology, University Hospital Hamburg Eppendorf ,Hamburg ,Germany
Wulf, Sonia;
Zugehörigkeit
Division of Translational Immunology, III. Department of Medicine, University Medical Center Hamburg-Eppendorf ,Hamburg ,Germany
Krebs, Christian F.;
GND
110935810
Zugehörigkeit
Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Hans-Knöll-Institute ,Jena ,Germany
Zipfel, Peter F.;
GND
131519859
Zugehörigkeit
Nephropathology Section, Institute of Pathology, University Hospital Hamburg Eppendorf ,Hamburg ,Germany
Wiech, Thorsten

Since the re-classification of membranoproliferative glomerulonephritis the new disease entity C3 glomerulopathy is diagnosed if C3 deposition is clearly dominant over immunoglobulins in immunohistochemistry or immunofluorescence. Although this new definition is more orientated at the pathophysiology as mediated by activity of the alternative complement pathway C3 glomerulopathy remains a heterogenous group of disorders. Genetic or autoimmune causes are associated in several but not in all patients with this disease. However, prognosis is poorly predictable, and clinicians cannot directly identify patients that might benefit from therapy. Moreover, therapy may range from supportive care alone, unspecific immune suppression, plasma treatment, or plasma exchange to complement inhibition. The current biopsy based diagnostic approaches sometimes combined with complement profiling are not sufficient to guide clinicians neither (i) whether to treat an individual patient, nor (ii) to choose the best therapy. With this perspective, we propose an interdisciplinary diagnostic approach, including detailed analysis of the kidney biopsy for morphological alterations and immunohistochemical staining, for genetic analyses of complement genes, complement activation patterning in plasma, and furthermore for applying novel approaches for convertase typing and complement profiling directly in renal tissue. Such a combined diagnostic approach was used here for a 42-year-old female patient with a novel mutation in the Factor H gene, C3 glomerulopathy and signs of chronic endothelial damage. We present here an approach that might in future help to guide therapy of renal diseases with relevant complement activation, especially since diverse new anti-complement agents are under clinical investigation.

Zitieren

Zitierform:
Zitierform konnte nicht geladen werden.

Rechte

Rechteinhaber: Copyright © 2022 Schmidt, Afonso, Perie, Heidenreich, Wulf, Krebs, Zipfel and Wiech

Nutzung und Vervielfältigung:
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.